# A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine

> **NCT06147895** · PHASE1 · COMPLETED · sponsor: **CHA Vaccine Institute Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Vaccine-Preventable Diseases
- Hepatitis B

## Interventions

- **BIOLOGICAL:** CVI-HBV-002

## Key facts

- **NCT ID:** NCT06147895
- **Lead sponsor:** CHA Vaccine Institute Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-09-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06147895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06147895, "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06147895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*